Oculis Holding AG
OCS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OCS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OCS
Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing therapies for ophthalmic diseases, with lead candidates OCS-01, Licaminlimab (OCS-02), and Privosegtor (OCS-05).
Key risk: No approved products or revenue
Market Cap
$678.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing therapies for ophthalmic diseases, with lead candidates OCS-01, Licaminlimab (OCS-02), and Privosegtor (OCS-05).
- Oculis has three lead product candidates: OCS-01, Licaminlimab (OCS-02), and Privosegtor (OCS-05), targeting retinal diseases, dry eye, and glaucoma [sec · filed 2025-03-11].
- As of December 31, 2025, the company reported cash and equivalents of $81.3M and total debt of $3.1M [latest reported financials].
- The company has never generated revenue from product sales and expects to continue incurring significant net losses [sec · filed 2026-03-04].
- Oculis has raised approximately CHF 392.7 million from leading investors since inception [sec · filed 2025-03-11].
- The company's management team has extensive backgrounds in drug discovery, clinical trials, regulatory affairs, and commercialization [sec · filed 2025-03-11].
What works
- Oculis is led by an experienced management team with a track record of advancing drug candidates through regulatory approval and successful commercialization [sec · filed 2025-03-11].
- The company has raised approximately CHF 392.7 million from leading investors, indicating strong financial backing [sec · filed 2025-03-11].
- Oculis has a pipeline of three product candidates targeting multiple ophthalmic indications, which could diversify its revenue sources if approved [sec · filed 2025-03-11].
What to weigh
- Oculis has never generated any revenue from product sales and anticipates continuing to incur significant net losses for the foreseeable future [sec · filed 2026-03-04].
- The company's success depends on the successful development, regulatory approval, and commercialization of its product candidates, which is highly uncertain [sec · filed 2026-03-04].
- Oculis will need substantial additional funding to complete development and commercialization, and its cash runway estimate is based on assumptions that may prove inaccurate [sec · filed 2026-03-04].
- The company has a concentration risk as its business relies on a limited number of product candidates and potential commercial partners [sec · filed 2025-03-11].
From the filings
Quoted directly from source documents.
Oculis has never generated revenue from product sales.
“We have never generated any revenue from product sales, and we may never generate revenue or be profitable.”
SEC filings · March 4, 2026
Oculis expects to continue incurring significant net losses.
“We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur significant and increasing net losses for the foreseeable future.”
SEC filings · March 4, 2026
Oculis's cash position as of December 31, 2025.
“As of December 31, 2025, we had CHF 213.0 million in cash, cash equivalents and short-term financial assets.”
SEC filings · March 4, 2026
Oculis's management team has a track record of advancing drugs through approval.
“Collectively, our management team has a track record of advancing new drug candidates through regulatory approval and successful commercialization.”
SEC filings · March 11, 2025
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Oculis has never generated product revenue and may never become profitable [sec · filed 2026-03-04].
- Dependence on three product candidates — Success hinges on OCS-01, Licaminlimab, and Privosegtor; failure of any could materially harm the business [sec · filed 2025-03-11].
- Need for additional financing — Substantial additional funding is required to complete development and commercialization; cash may be used faster than expected [sec · filed 2026-03-04].
- Concentration risk — Reliance on a limited number of products and partners increases vulnerability to adverse events [sec · filed 2025-03-11].
What to watch
- Clinical trial results and regulatory submissions for OCS-01, Licaminlimab, and Privosegtor [sec · filed 2026-03-04].
- Cash burn rate and any additional financing rounds to support operations beyond the next 12 months [sec · filed 2026-03-04].
- Progress toward commercialization and potential partnerships to mitigate concentration risk [sec · filed 2025-03-11].
Sources: SEC filings · Generated August 24, 2026 · How we verify sources →
Run Oculis Holding AG through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Oculis Holding AG facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
54
Total value held
$466.1M
| Holder | Shares | Value |
|---|---|---|
| eqt fund management s.a r.l. | 5,900,294 | $156.9M |
| gildi - lifeyrissjodur | 2,430,401 | $64.3M |
| pivotal bioventure partners investment advisor llc | 1,680,283 | $44.7M |
| wellington management group llp | 1,345,728 | $35.8M |
| perceptive advisors llc | 987,654 | $26.3M |
| millennium management llc | 913,034 | $24.3M |
| adage capital partners gp, l.l.c. | 833,209 | $22.2M |
| eventide asset management, llc | 430,000 | $11.4M |
| woodline partners lp | 402,400 | $10.7M |
| nan fung group holdings ltd | 350,745 | $9.3M |
Showing top 10 of 54 institutional holders of Oculis Holding AG. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 0.9%
- Days to cover
- 2.1
- Shares short
- 428,702
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OCS short interestFrequently asked questions
What is the AI investment thesis for Oculis Holding AG?
Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing therapies for ophthalmic diseases, with lead candidates OCS-01, Licaminlimab (OCS-02), and Privosegtor (OCS-05).
Who is the CEO of Oculis Holding AG?
Dr. Riad Sherif M.B.A., M.D. is the chief executive officer of Oculis Holding AG (OCS).
Where is Oculis Holding AG headquartered?
Oculis Holding AG (OCS) is headquartered in Zug, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.